Date:1/24/2013

62,180$
(1,498)$
560,682Reimbursable out-of-pocket expenses46,96446,964Total revenues609,144--(1,498)607,646Costs and expenses:  Cost of revenue395,8413,613(3,697)395,757  Reimbursable out-of-pocket expenses46,96446,964  Selling, general and administrative92,823(9,013)(117)83,693  Depreciation and amortization30,423(1,178)(534)28,711  Goodwill impairment charge---Total costs and expenses566,051(10,191)3,613(4,348)555,125Income from operations43,09310,191(3,613)2,85052,521Other expense, net:  Interest expense, net1,1531,153  Foreign exchange transaction loss, net173173  Impairment of equity investment--  Gain on sale of investment--  Loss on sale of business--Other expense, net1,326---1,326Income before taxes and equity investee earnings41,76710,191(3,613)2,85051,195Taxes on income7,8703,223(1,111)88410,866Equity investee earnings--Net income $
33,897$
,968$
(2,502)$
,966$
40,329Basic earnings per share$
.63$
.13$
(0.05)$
.04$
.75Weighted average shares outstanding - basic53,698,33453,698,33453,698,33453,698,33453,698,334Diluted earnings per share$
.61$
.13$
(0.05)$
.04$
.73Weighted average shares outstanding - diluted55,197,96855,197,96855,197,96855,197,96855,197,968(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.(2) Reduction of inventory impairment based upon determination of actual impaired inventory.(3) Represents results of operations at sites that were closed during the period. COVANCE INC.GAAP to Pro Forma ReconciliationQ4 2011(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring Activities ⁽¹⁾Other
Charges ⁽²⁾Income Tax Items ⁽³⁾Pro FormaNet revenues$
532,478$
532,478Reimbursable out-of-pocket expenses49,90749,907Total revenues582,385---582,385Costs and expenses:  Cost of revenue371,852371,852
'/>"/>

SOURCE Covance Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
9. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012